Page last updated: 2024-11-10

ostruthin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5281420
CHEMBL ID1812645
CHEBI ID69833
SCHEMBL ID2936116
SCHEMBL ID2936121
MeSH IDM0052811

Synonyms (37)

Synonym
coumarin, 6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-,(e)-
ostruthine
nsc83434
2h-1-benzopyran-2-one,6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-,(e)-
6-[(2e)-3,7-dimethylocta-2,6-dienyl]-7-hydroxy-chromen-2-one
ACON1_001218
coumarin,7-dimethyl-2,6-octadienyl)-7-hydroxy-, (e)-
2h-1-benzopyran-2-one,7-dimethyl-2,6-octadienyl)-7-hydroxy-, (e)-
nsc-83434
6-geranyl-7-hydroxycoumarin
MEGXP0_001198
C09281
148-83-4
ostruthin
6-[(2e)-3,7-dimethylocta-2,6-dienyl]-7-hydroxychromen-2-one
CHEMBL1812645
chebi:69833 ,
xhk3rr9bor ,
nsc 83434
ccris 8087
2h-1-benzopyran-2-one, 6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-, (e)-
unii-xhk3rr9bor
coumarin, 6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-, (e)-
6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxycoumarin
(e)-6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-2h-1-benzopyran-2-one
(e)-6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxycoumarin
6-(3,7-dimethyl-2,6-octadienyl)umbelliferone
ostruthin [mi]
(e)-6-(3,7-dimethylocta-2,6-dien-1-yl)-7-hydroxy-2h-chromen-2-one
SCHEMBL2936116
SCHEMBL2936121
2h-1-benzopyran-2-one,6-[(2e)-3,7-dimethyl-2,6-octadien-1-yl]-7-hydroxy-
6-geranyl-7-hydroxycoumarin, >=95% (lc/ms-elsd)
2h-1-benzopyran-2-one, 6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-, (e)- (9ci)
Q21547160
DTXSID601318569
AKOS040735765
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
terpene lactone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID611882Antiproliferative activity in primary rat aortic VSMC assessed as inhibition of serum-induced DNA synthesis pretreated 30 mins prior serum addition measured after 48 hrs by BrdU incorporation assay2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation.
AID611885Cytotoxicity against primary rat aortic VSMC as cell viability at 30 uM by trypan blue exclusion assay (Rvb = 98+/-2%)2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation.
AID611886Antiproliferative activity against serum-stimulated primary rat aortic VSMC after 30 mins by resazurin conversion assay2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation.
AID611884Antiproliferative activity against serum-stimulated primary rat aortic VSMC at 30 uM after 30 mins by resazurin conversion assay2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's2 (25.00)18.2507
2000's1 (12.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.00 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]